Two-Component Direct Fluorescent-Antibody Assay for Rapid Identification of Bacillus anthracis by De, Barun K. et al.
BIOTERRORISM-RELATED ANTHRAX
1060 Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002
Two-Component Direct 
Fluorescent-Antibody Assay 
for Rapid Identification of 
Bacillus anthracis
Barun K. De,* Sandra L. Bragg,* Gary N. Sanden,* Kathy E. Wilson,* Lois A. Diem,* 
Chung K. Marston,* Alex R. Hoffmaster,* Gwen A. Barnett,* Robbin S. Weyant,* 
Teresa G. Abshire,† John W. Ezzell,† and Tanja Popovic* 
A two-component direct fluorescent-antibody (DFA) assay, using fluorescein-labeled monoclonal antibodies
specific to the Bacillus anthracis cell wall (CW-DFA) and capsule (CAP-DFA) antigens, was evaluated and
validated for rapid identification of B. anthracis. We analyzed 230 B. anthracis isolates; 228 and 229 were
positive by CW-DFA and CAP-DFA assays, respectively. We also tested 56 non–B. anthracis strains; 10 B.
cereus and 2 B. thuringiensis were positive by the CW-DFA assay, and 1 B. megaterium strain was positive
by CAP-DFA. Analysis of the combined DFA results identified 227 of 230 B. anthracis isolates; all 56 strains
of the other Bacillus spp. were negative. Both DFA assays tested positive on 14 of 26 aging clinical speci-
mens from the 2001 anthrax outbreak investigation. The two-component DFA assay is a sensitive, specific,
and rapid confirmatory test for B. anthracis in cultures and may be useful directly on clinical specimens.
he potential use of Bacillus anthracis as a biological
weapon has long been recognized (1–5). Recently, the
profound impact of B. anthracis on public health was demon-
strated during the bioterrorism-related anthrax outbreak in the
United States (6). Rapid diagnosis played an important role
during the outbreak and aided in implementing appropriate
public health measures in a timely manner. Although several
standard microbiologic assays are available to identify B.
anthracis  (7),  they primarily lack timeliness in producing
results. 
Earlier studies demonstrated the advantages of immunoflu-
orescence assays, based on polyclonal antibodies to B. anthra-
cis cell-surface antigens, for identifying B. anthracis isolates
(8) and directly evaluating clinical specimens from infected
guinea pigs (9). However, the limitations of polyclonal anti-
bodies, such as the problem of cross-reactivity with closely
related Bacillus species known as the B. cereus complex (10),
were also apparent. Over the past decade, monoclonal antibod-
ies specific to the B. anthracis cell wall polysaccharide antigen
were shown to be useful in identification of B. anthracis infec-
tion (11,12). Vegetative B. anthracis cells constitutively
express the galactose/N-acetylglucosamine polysaccharide
cell wall antigen (13,14). In addition, during infection or
growth in nutrient-rich media in an elevated CO2 environment,
B. anthracis cells produce a poly-γ -D-glutamic acid capsule,
which is synthesized by the products of genes located on the
pXO2 plasmid (15). The capsule masks the cell wall polysac-
charide (11); however, the polysaccharide becomes detectable
in aging clinical samples (N. Woollen, pers. comm.).In this
study, we have evaluated and validated a two-component
direct fluorescent-antibody (DFA) assay, using the monoclonal
immunoglobulin (Ig) M antibody EAII-6G6-2-3 against the
cell wall polysaccharide antigen (CW) (12) and the mono-
clonal IgG antibody FDF-1B9 against the capsule antigen
(CAP) (16) for rapid identification of B. anthracis. In addition
to use on isolates, this rapid DFA assay was applied success-
fully to detect B. anthracis directly in clinical specimens from
several patients with laboratory-confirmed inhalational
anthrax during the 2001 bioterrorism-associated anthrax out-
break in the United States (6,17). 
Materials and Methods
Bacterial Isolates
B. anthracis Isolates (n=230)
Eighty-one  B. anthracis isolates from different sources
(human, animal, and environmental) representing broad geo-
graphic and temporal (1939–1997) diversity were selected
from culture collections at the Meningitis and Special Patho-
gens Branch, Centers for Disease Control and Prevention,
Atlanta, Georgia. Six of these isolates were free of pXO1 or
pXO2 plasmids. An additional 149 B. anthracis isolates,
obtained from powders (n=4), 10 patients (n=26), and environ-
mental sources (n=125) during the investigation of the U.S.
bioterrorism-associated anthrax outbreak from October 5 to
December 21, 2001, were included.
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA;
and †U.S. Army Medical Institute of Infectious Diseases, Fort Detrick,
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TEmerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1061
BIOTERRORISM-RELATED ANTHRAX
Other Bacillus spp. (n=56)
Five closely related Bacillus species—B. cereus (n=23), B.
megaterium (n=11), B. subtilis (n=9), B. thuringiensis (n=12),
and B. mycoides (n=1)—were selected to test the specificity of
the DFA assays. Most B. cereus isolates (n=20) were from dif-
ferent sources (environmental, food, human, and animal) rep-
resenting broad geographic and temporal (1957–2000)
diversity. 
Control Strains (n=2)
B. anthracis Pasteur (ATCC 4229) and B. cereus (ATCC
14579) were used as positive and negative controls, respec-
tively, for both CW- and CAP-DFA assays. The control strains
were stored at 4°C as spore suspensions in water. All other
strains were kept at –70°C as spore suspensions in water or in
2.5% heart infusion broth (HIB) containing 20% glycerol. All
strains were identified by standard microbiologic procedures
(7), and confirmatory identification of B. anthracis strains was
performed according to the Laboratory Response Network
testing algorithm (5) using a battery of tests including the DFA
assay described in this study.
Clinical Specimens
Twenty-six clinical specimens (stored at 4° for >1 month),
including aerobic and anaerobic blood cultures (n=11), various
body fluids (n=6), pleural fluids (n=4), lung tissues (n=3), and
lymph nodes (n=2), were collected from seven patients with
laboratory-confirmed inhalational anthrax from October
through December 2001 (6,17,18).
Preparation of Fluorescein-Antibody Conjugates
Two monoclonal antibodies, EAII-6G6-2-3 (12) and FDF-
1B9 (16), were purified by HiTrap SP Gradifrac cation
exchange chromatography (Pharmacia, Peapack, NJ) to homo-
geneity and conjugated to fluorescein isothiocyanate (FITC),
according to a standard protocol (Molecular Probes, Eugene,
OR). The anti-cell wall (anti-CW FITC) and anti-capsule (anti-
CAP FITC) conjugates were lyophilized in HEPES buffer
(0.05 M HEPES, pH 7.0, 0.10% glycine, 0.01 M d-sorbitol,
0.15 M KCl, and 5% d-trehalose) containing 1% bovine serum
albumin (Cohn Fraction V) (Sigma Chemical Co., St. Louis,
MO). The working antibody solutions (50 µg/mL) were pre-
pared in 50% glycerol in water and stored at –20°C or 4°C. 
Preparation of Cell Suspensions for DFA Assays
Vegetative Cells for the CW-DFA Assay
For each control and test strain, fresh vegetative cells were
grown by plating stock spore suspension (1 µL) on trypticase
soy agar with 5% sheep blood (SBA) (BBL Microbiology Sys-
tems, Cockeysville, MD) and incubating aerobically overnight
at 37°C. The cell suspensions were prepared by suspending
one loop (1 µL) of the SBA culture in 100 µL of 10 mM phos-
phate-buffered saline/0.3% Tween 20, pH 7.2 (PBST) and
adjusting the concentration to ~107 cells/mL (equivalent to a
0.5 McFarland standard).
Encapsulated Cells for the CAP-DFA Assay
For each control and test strain, encapsulated cells were
grown by transferring an overnight growth of fresh vegetative
cells (~107  cells) into either 450 µL of defibrinated horse
blood (Lampire Biological Labs, Pipersville, PA) or 2.5% HIB
supplemented with 50% inactivated horse serum (Sigma) and
0.8% sodium bicarbonate and incubating at 37°C for 3 h.
Clinical Specimens
For liquid specimens, ~90 µL of each specimen was
diluted with 10 vol of PBST; the cells were recovered by cen-
trifugation (14, 000 X g for 3 min). After removal of superna-
tant, the cells were suspended in 90 µL of the residual
supernatant. Solid tissues (e.g., lymph nodes, lung tissues)
were homogenized with a small disposable tissue grinder
(Kendall Co., Mansfield, MA) in 100–250 µL of HIB. Forty-
five microliters of the homogenates or cell suspensions was
used directly in the DFA assays.
CW- and CAP-DFA Assays
To evaluate the sensitivity and specificity of both DFA
assays, 45-µL cell suspensions were mixed with 5 µL of anti-
CW FITC or anti-CAP FITC conjugate and incubated at 37°C
for 30 min. After the reaction mixture was diluted with 1 mL
PBST, the cells were recovered by centrifugation (14, 000 X g
for 3 min) and washed once more with 1 mL deionized water.
After the second centrifugation, most of the supernatant was
aspirated, and the cell pellet was suspended in ~100 µL of the
residual water. A 2-µL volume of the suspension was trans-
ferred to one well of a 12-well Teflon-coated microscope slide
(Cel-Line/Erie Scientific Co., Portmouth, NH), air-dried, and
mounted with DAKO faramount aqueous medium (DAKO
Co., Carpinteria, CA). The labeled cells were visualized on a
UV microscope with a 40X or 100X objective with oil. When
B. anthracis cells exhibited whole-body bright green fluores-
cence against a dark background, the reaction was read as pos-
itive. A negative reaction had cells that did not show
fluorescence. An identical procedure was used to stain 45-µL
volumes of the processed clinical specimens. DFA was
reported as positive for B. anthracis only when both CW- and
CAP-DFA assays were positive.
To determine the lower limits of detection for both CW-
and CAP-DFA assays, serial 10-fold dilutions (107–103 cells/
mL) of the fresh cells of the control strains (Pasteur strain and
B. cereus) were prepared, and 45-µL volumes of cell suspen-
sion were used as described.
Results
Of 230 B. anthracis isolates  analyzed, 228 (99%) were
positive in the CW-DFA (Table 1) (19). Two isolates (one
environmental isolate from a mill and one from a cow) thatBIOTERRORISM-RELATED ANTHRAX
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were negative by the CW-DFA assay were collected in Ala-
bama in the 1950s (20). Among the non–B. anthracis isolates,
10 (43%) of 23 B. cereus and 2 (16.7%) of 12 B. thuringiensis
were also CW-DFA positive. All 9 B. subtilis, 11 B.
megaterium, and 1 B. mycoides strains were negative (Table
2). In all the positive reactions, >99% of the B. anthracis
cells expressed cell wall polysaccharide antigen so that
characteristic chain-forming rods were visualized with bright
fluorescence (Figure, panel A). All the 149 B. anthracis iso-
lates from the 2001 anthrax outbreak investigation were posi-
tive (Table 1). The sensitivity and specificity of the CW-DFA
assay were 99% (228/230, 95% confidence intervals [CI]) and
78.6% (44/56, 95% CI), respectively. 
All but 1 (99.7%) of the 230 B. anthracis isolates tested
were CAP-DFA positive; the single exception was a B. anthra-
cis Sterne strain cured of plasmid pXO2 (Table 1) and, thus, as
expected, it was unencapsulated. Of the 56 non–B. anthracis
isolates tested, only 1 B. megaterium strain was positive by the
CAP-DFA assay (Table 2). This environmental isolate, col-
lected during the bioterrorism-associated anthrax outbreak,
was identified as B. megaterium by both standard microbio-
logic procedures (7) and sequencing of the 16S ribosomal
RNA gene (data not shown). All the 149 B. anthracis isolates
from the 2001 anthrax outbreak were CAP-DFA positive.
Most of the encapsulated B. anthracis cells (>90%) were
labeled uniformly (Figure, panel B), and they demonstrated
similar fluorescence to that of the cell wall staining. The sensi-
tivity and specificity of the CAP-DFA assay were 99% (229/
230, 98% to 100% CI) and 98% (55/56, 90% to 100% CI),
respectively.
Analysis of the combined DFA assay results showed that
227 of 230 B. anthracis isolates were positive, yielding a spec-
ificity of 99% (95% CI, 96% to 100%). Similarly, all 56 of the
other Bacillus strains were negative, for a specificity of 100%
(95% CI, 94% to 100%). The current two-component DFA
assay was capable of detecting as low as ~104 cells/mL of veg-
etative or encapsulated B. anthracis cells from cultures.
Fourteen of the 26 clinical specimens analyzed from seven
patients with laboratory-confirmed anthrax were positive in
both the CW- and CAP-DFA assays (Table 3). Furthermore,
most blood specimens (8 of 12) were positive by both assays.
Most blood specimens were also positive by culture (n=5) and
polymerase chain reaction (PCR) (n=4) assays. Among the
other clinical specimens tested, two lung tissues, one lymph
node, two pleural fluids, and one unspecified body fluid were
positive by both DFA assays. Four of these six specimens were
negative by culture, and three of them were positive by PCR.
Most of these specimens were collected from patients treated
with antimicrobial agents before or on the day of specimen
collection. All other clinical specimens, such as heart fluid,
pericardial fluid, and chest fluids, were negative by both DFA
assays. 
Discussion
Recent events have emphasized the need for rapid, sensi-
tive, and specific assays for the confirmatory identification of
B. anthracis and detection of this agent directly in clinical
specimens. The availability of monoclonal antibodies recog-
nizing the cellwall polysaccharide and capsule antigens of
vegetative cells provides the means to rapidly differentiate B.
anthracis from other Bacillus spp. Although some B. cereus
and B. thuringiensis strains express the galactose/N-acetylglu-
cosamine polysaccharide antigen, such organisms lack the
poly-γ -D-glutamic acid capsule of B. anthracis. Thus, detec-
tion of both antigens by a DFA assay is highly specific for B.
anthracis. In this study, we evaluated a two-component DFA
assay employing monoclonal antibodies specific for these two
antigens for confirmatory identification of diverse B. anthracis
strains and for detection of B. anthracis directly in clinical
specimens. We found that this approach provided sensitive and
specific confirmation of B. anthracis cultures within 3–6 h. In
addition, this approach detected B. anthracis directly in clini-
cal specimens of seven patients with laboratory-confirmed
inhalational anthrax.
The expression of DFA targets could vary by B. anthracis
strain, which would adversely affect the sensitivity of the test.
Consequently, we first evaluated the sensitivity of the two
DFA assays independently against 230 B. anthracis isolates.
Because of the diversity of B. anthracis isolates tested, our
results should be applicable to very divergent strains from dif-
ferent sources. The sensitivity for B. anthracis was high (99%)
for each DFA. The CW-DFA assay failed to detect only two
Figure. Direct fluorescent-antibody (DFA) staining of Bacillus anthracis
cells. Panel A (cell wall DFA) and Panel B (capsule DFA) correspond to
1) Positive control (B. anthracis Pasteur strain), 2) Test isolate
#2002013601 (environmental specimen, 2001 U.S. anthrax outbreak),
and 3) Clinical specimen #2002007069 (lung tissue of patient 1, 2001
U.S. anthrax outbreak), original magnification x 400.Emerging Infectious Diseases  •  Vol. 8, No. 10, October 2002 1063
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isolates, and the CAP-DFA assay was negative only for the
strain cured of the pXO2 plasmid, rendering it unencapsulated.
This level of specificity of this two-component DFA assay was
affirmed, as every outbreak-associated B. anthracis isolate
tested positive. We determined that the minimal number of
CFU detectable by either assay was 104 CFU/mL, a level com-
parable with that of many PCR assays. 
The lower limit of detection is not a limiting parameter of
the confirmatory test’s sensitivity because unlimited quantities
of cells are available for testing after primary culture. How-
ever, specificity is crucial; CAP-DFA assay specificity was
very high (98%), but the cell-wall assay specificity was only
78.6% compared with the previous studies on the limited
cross-reactivity with the other Bacillus spp. (12). Almost 93%
of the CW-DFA assay false-positive isolates were B. cereus or
B.  thuringiensis. Only one B. megaterium strain was CAP-
DFA positive. However, confirmation of virulent B. anthracis
strains requires that both assays be positive; compliance with
that requirement resulted in 100% specificity because no test
isolate except B. anthracis was positive in both assays (20).
Again, the high specificity of the two-component DFA assay
was reflected in its performance on the 149 tested isolates
from the 2001 anthrax outbreak. These isolates were shown to
be indistinguishable from each other based on the molecular
analysis, as delineated by Hoffmaster et al. (20). The DFA
assay specificity was similar to the highest levels achieved by
PCR assays and the phenotypic confirmatory identification
scheme described previously (5,7). However, the two-compo-
nent DFA assay requires less sophisticated equipment,
reagents, and controls and smaller dedicated space than PCR,
and is only slightly less rapid. The DFA assay is considerably
more rapid than the standard confirmatory identification meth-
ods and offers a substantial specificity advantage.
The availability of clinical material from several anthrax
patients from the 2001 outbreak provided an additional oppor-
tunity to evaluate this two-component DFA. We used the DFA
assay to detect B. anthracis directly in the limited number of
available clinical specimens and compared these results with
those from culture and PCR (21). We noted that all DFA-posi-
tive specimens reacted with both components of the assay,
suggesting that the sensitivities and specificities of the respec-
tive assays were similar, as we previously showed for cultures.
The two-component assay detected B. anthracis in all speci-
mens that were positive by culture and the confirmatory identi-
fication regimen. Moreover, four of the five culture-negative
specimens that were positive by DFA assay were also positive
by PCR. The fifth such specimen (patient 2, unspecified fluid)
and two additional specimens (patient 1, lung tissues) that
were not cultured were positive only by the DFA assay. Four
other specimens from these two patients were PCR positive,
suggesting that the discordant DFA assay results were true
positives. None of the specimens collected after the patient
received antimicrobial therapy were culture positive, but four
specimens collected from four patients concurrent with (n=1)
or after (n=3) antimicrobial therapy were DFA positive.
Together, these results suggest that the DFA assay is specific
for B. anthracis and that its sensitivity is similar to that of cul-
ture or perhaps considerably greater if the patient is receiving
antimicrobial agents. Conversely, six PCR-positive specimens
were negative by the DFA assay, indicating that the latter may
be relatively less sensitive. The two DFA positive/PCR-nega-
tive specimens indicate that only performing all available
Table 2. Results of cell wall and capsule direct fluorescent-antibody 
assays for 56 strains of five Bacillus speciesa
Species No. of strains
CW-DFA 
(% positive)
CAP-DFA 
(% positive)
B. cereus 23 10 (43) 0 (0)
B. thuringiensis 12 2 (17) 0 (0)
B. megaterium 11 0 (0) 1 (11)
B. mycoides 1 0 (0) 0 (0)
B. subtilis 9 0 (0) 0 (0)
Total 56 12 (21) 1 (1.7)
aDFA, direct fluorescent-antibody assay; CW, cell wall; CAP, capsule.
Table 1. Origin, designations, and results of cell wall and capsule direct fluorescent-antibody assays for 230 Bacillus anthracis isolatesa
Origin 
No. of 
isolates Temporal range and geographic origin MLVA genotypes representedb
CW-DFA
(% positive)
CAP-DFA
(% positive)
Human isolates 31 1943–1997; Africa, Asia, Australia, 
Europe, North America
3,4,22,23,28,32,34,35,36,37,41,
43,44, 45,50,66,68
31 (100) 31 (100)
Animal isolates 29 1939–1997; Africa, Asia, Australia, 
Europe, North and South America
3,10,20,26,29,30,35,38,40,45,48,49,
51,55,57,78,80,81,84,85,87, 89
29 (100) 29 (100)
Environmental isolates (e.g., soil, 
burial sites, wool, tannery, mill)
16 1950–1993; Africa, Asia, Europe, and 
North America
13,14,21,24,47,62,69,73,77,79,82 15 (94) 16 (100)
pX01 plasmid cured 4 1950–1974; North America 3 (75) 4 (100)
pX02 plasmid cured 1 Africa 1 (100) 0 (0)
2001 anthrax outbreak 149 October 2001; United States 62c 149 (100) 149 (100)
Total 230  228 (99) 229 (99.6)
aDFA, direct fluorescent antibody assay; CW, cell wall; CAP, capsule; MLVA, multiple-locus variable-number tandem repeat analysis.
bKeim P, et al. J Bacteriol 2000;182:2928–36 (19).
cHoffmaster et al. Emerg Infect Dis 2002;8:1111-6 (20).BIOTERRORISM-RELATED ANTHRAX
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assays on specimens may maximize diagnostic sensitivity. The
two-component DFA assay rapidly detected B. anthracis in all
seven anthrax patients, suggesting that its predictive value
may have diagnostic relevance. However, the numbers of
specimens and patients in this evaluation were limited.
DFA assays have traditionally been used to rapidly identify
bacterial cultures and to directly detect bacterial disease agents
in infected clinical specimens. The extensive use of such
assays depends on their ability to sensitively and specifically
detect target organisms and to predict the diseases they cause.
We report for the first time an evaluation of a two-component
DFA assay to confirm the identity of presumptive B. anthracis
cultures and to detect this agent in clinical specimens. The cur-
rent assay had excellent sensitivity and specificity as a rapid
confirmatory test for B. anthracis cultures performed in a real-
time fashion in an outbreak setting. The assay also detected B.
anthracis in a limited number of specimens from anthrax
patients. However, we recommend that this latter application
be limited to a presumptive role in the laboratory diagnosis of
anthrax, until positive and negative predictive values are better
defined by future evaluations in animal models and human
populations with high anthrax prevalence or outbreaks.
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